Drugs / HRS-6257
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07301333 | Dec 2025 → May 2026 overdue | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-6257 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07301333 ↗ |
| Route | Oral | “multiple oral doses of HRS-6257” NCT07301333 ↗ |